## Why option 1 is right The structure marked **D** (NT-proBNP) is the N-terminal cleavage product released in equimolar amounts with active BNP from ventricular myocytes in response to wall stretch from increased ventricular filling pressures. NT-proBNP has a significantly longer half-life (60–120 minutes) compared to BNP (20 minutes), making it more stable for laboratory measurement and less subject to acute fluctuations. This stability is the primary reason NT-proBNP is preferred for diagnostic confirmation of heart failure in clinical practice, particularly in the Indian healthcare setting where sample transport times and laboratory turnaround may vary. [Guyton & Hall 14e Ch 22; Harrison 21e Ch 252] ## Why each distractor is wrong - **Option 2**: NT-proBNP is produced by both atria and ventricles in response to volume and pressure stress; it is not exclusive to the left ventricle. BNP is also produced by both chambers. This option conflates specificity with anatomical origin and is incorrect. - **Option 3**: NT-proBNP is actually affected by renal function. Decreased renal clearance of NT-proBNP leads to elevated levels in chronic kidney disease, which is a known confounder. This option directly contradicts the clinical anchor. - **Option 4**: NT-proBNP is the *inactive* cleavage product; the active form is BNP itself. NT-proBNP does not directly cause vasodilation or natriuresis. This is a fundamental mechanistic error. **High-Yield:** NT-proBNP > BNP for diagnosis because: longer half-life (60–120 vs 20 min), more stable in transit, age-adjusted cutoffs (< 50 yr: > 450; 50–75 yr: > 900; > 75 yr: > 1800 pg/mL), and negative predictive value < 300 pg/mL rules out HF. [cite: Guyton & Hall 14e Ch 22; Harrison 21e Ch 252]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.